Oxis Turbuhaler (formoterol) / AstraZeneca - LARVOL DELTA

AstraZeneca to Inject Another USD250 Million Into Its Asthma Inhaler Plant in China's Qingdao (Digital Journal) - "AstraZeneca will invest an additional USD250 million in its asthma inhaler factory in Qingdao, eastern Shandong province as the British-Swedish drugs giant remains upbeat about the country's growth prospects...The extra investment will bring the total in the factory, which will produce its Budesonide, Glycopyrronium Bromide and Formoterol Fumarate inhalers for chronic obstructive pulmonary diseases such as asthma, to USD700 million, AstraZeneca said..."

Commercial • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

What medicines lower their price in 2021? [Google translation] (Ok Diary) - "Among the drugs that will be more reduced from January 1, 2021 are those that treat asthma. These are, according to agencies, those of compounds by active principles such as ipratropium bromide, budesonide, fluticasone and formoterol."

Pricing • Asthma • Respiratory Diseases

AstraZeneca PLC - Third quarter and nine months results 2011 (AstraZeneca) - Symbicort sales in the US were $201 million in the third quarter a 15% increase over last year and US sales for past nine months were $604M an increase of 14%; Symbicort sales in other markets in the third quarter were $554M in Japan,Canada, Australia and emerging Europe 7% ahead of the third quarter last year; Pulmicort in the third quarter were down 15% to $52M and nine months sales were down by 8%; Due to the lack of efficacy in a P2b trial, the decision was made to discontinue the development programme for MEDI-528

Quarterly results • Sales update • Asthma

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma (clinicaltrials.gov) - P4; N=400; Active, not recruiting; Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.; Recruiting -> Active, not recruiting ; N=500 -> 400

Enrollment change • Enrollment closed • Asthma • Biosimilar • Immunology • Inflammation

Oxidative stress-induced corticosteroid insensitivity is reversed by formoterol via inhibition of PI3K signalling in peripheral blood mononuclear cells from patients with COPD and severe asthma (ERS 2011) - Peripheral blood mononuclear cells (PBMCs) from patients with severe asthma and COPD are less sensitive to DEX vs. healthy volunteers; FM (10-9M) and salmeterol (SM, 10-8M) reversed DEX insensitivity in PBMCs of severe asthma; FM restored corticosteroid sensitivity via inhibition of PI3K signalling

Mechanism of action • Asthma